Table 1 Patient characteristics
Characteristic | Everolimus 5 mg/day (n = 12) | Everolimus 10 mg/day (n = 12) |
|---|---|---|
Median (range) age, y | 55 (27-75) | 56 (32-75) |
Sex, n (%) | Â | Â |
   Male | 5 (41.7) | 4 (33.3) |
   Female | 7 (58.3) | 8 (66.7) |
WHO performance status, n (%) | Â | Â |
   0 | 3 (25.0) | 1 (8.3) |
   1 | 9 (75.0) | 9 (75.0) |
   2 | 0 | 2 (16.7) |
Prior antineoplastic therapy, n (%) | Â | Â |
   Surgery | 11 (91.7) | 10 (83.3) |
   Radiotherapy | 3 (25.0) | 3 (25.0) |
   Chemotherapy | 10 (83.3) | 10 (83.3) |
   Targeted therapy | 5 (41.7) | 5 (41.7) |
   Immunotherapy | 3 (25.0) | 2 (16.7) |
   Hormonal therapy | 2 (16.7) | 0 |